$PPHM Form 8-K

0
603

Form 8-K for PEREGRINE PHARMACEUTICALS INC


17-Mar-2016

Entry into a Material Definitive Agreement, Material Modification t

Item 1.01. Entry into a Material Definitive Agreement.On March 16, 2016, Peregrine Pharmaceuticals, Inc., a Delaware corporation (the “Company”), entered into an Amended and Restated Rights Agreement (the “Amended Rights Agreement”) with Broadridge Corporate Issuer Solutions, Inc., as rights agent (the “Rights Agent”). The Amended Rights Agreement amends and restates the Rights Agreement, dated as of March 16, 2006, between the Company and the Rights Agent (the “Prior Rights Agreement”).

Under the Prior Rights Agreement, the rights set forth therein are set to expire on the close of business on March 16, 2016. The Amended Rights Agreement extends the date of expiration, such that the rights set forth in the Amended Rights Agreement will continue in effect until March 16, 2021, unless earlier redeemed or exchanged by the Company, or the closing of any merger or other acquisition transaction involving the Company at which time the rights are terminated, as further set forth in the Amended Rights Agreement.

A copy of the Amended Rights Agreement is attached as Exhibit 4.1 to this Current Report and is incorporated herein by reference. A copy of the Prior Rights Agreement as originally executed is attached as Exhibit 4.19 to the Company’s Current Report on Form 8-K filed on March 17, 2006 and is incorporated herein by reference. This foregoing summary of the Amended Rights Agreement does not purport to be complete and is subject to and qualified in its entirety by reference to the Amended Rights Agreement attached hereto as Exhibit 4.1.

 

Item 3.03. Material Modification to Rights of Security Holders.The disclosures set forth in Item 1.01 above are incorporated herein by reference into this Item 3.03.

 

Item 9.01. Financial Statements and Exhibits.(d) Exhibits

Exhibit No.     Description

4.1             Amended and Restated Rights Agreement, dated March 16, 2016,
                between Peregrine Pharmaceuticals, Inc. and Broadridge Corporate
                Issuer Solutions, Inc., as Rights Agent.

LEAVE A REPLY

Please enter your comment!
Please enter your name here